Mflusiva 2026-2027 (influenza virus vacc tv 2026-27(50 yr up) mRNA/PF)

It isessential that the manufacturer's labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:

For IM use.

Administer influenza vaccine mRNA as a single 0.38 mL dose.

No dosing information is available for this tab.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.

Vaccines/Pariglasgene Brecaparvovec

SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.

MECHANISM OF ACTION: Pariglasgene brecaparvovec therapy may decrease the effectiveness of vaccines. The mechanism is not known.(1)

CLINICAL EFFECTS: The expected serum antibody response may not be obtained.(1)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: The US manufacturer of pariglasgene brecaparvovec states that vaccines should be avoided for 1 month prior to pariglasgene brecaparvovec administration.(1)

DISCUSSION: Pariglasgene brecaparvovec therapy may decrease the effectiveness of vaccines.(1)

There are no severe interactions for this drug.

Moderate Interaction: Assess the risk to the patient and take action as needed.

Vaccines/Hepatitis B Vaccine (FENDRIX)

SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.

MECHANISM OF ACTION: No data is available on the concurrent administration of the hepatitis B vaccine Fendrix and other vaccines.(1)

CLINICAL EFFECTS: It is unknown if concurrent administration of the hepatitis B vaccine Fendrix and other vaccines will affect the efficacy of either vaccine.(1)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: The Swedish manufacturer of Fendrix states that since there is no data available for the concurrent administration of Fendrix with other vaccines, the administration of Fendrix and other vaccines should be separated by 2 to 3 weeks.(1)

DISCUSSION: No data is available on the concurrent administration of the hepatitis B vaccine Fendrix with other vaccines.(1)

History of severe allergic reaction (e.g., anaphylaxis) to influenza vaccine, mrna or any of its components.

There are no contraindication contraindications for this drug.

• Guillain-barre syndrome

There are no moderate contraindications for this drug.

*In participants 50 through 64 years of age, the most commonly reported (>=10%) adverse reactions were injection site pain (68.7%), fatigue (48.1%), headache (41.9%), myalgia (40.6%), arthralgia (31.5%), chills (27.5%), and axillary (underarm) swelling or tenderness (20.3%).

*In participants 65 years of age and older, the most commonly reported (>=10%) adverse reactions were injection site pain (62.9%), fatigue (42.1%), headache (33.7%), myalgia (30.2%), arthralgia (24.1%), chills (18.1%), and axillary (underarm) swelling or tenderness (14.2%).

There are no severe adverse reactions for this drug.

More Frequent

• Arthralgia
• Axillary swelling or tenderness
• Chills
• Fatigue
• Headache disorder
• Injection site pain
• Injection site sequelae
• Myalgia
• Nausea
• Vomiting

Less Frequent

• Fever
• Injection site erythema

Rare or Very Rare

• Syncope

No enhanced messaging available.

Safety and effectiveness of influenza vaccine mRNA have not been established in persons younger than 18 years of age.

All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Influenza vaccine mRNA is not approved for use in persons younger than 50 years of age. Available data on influenza vaccine mRNA administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy.

A developmental toxicity study was performed in female rats administered a vaccine containing 100 mcg of nucleoside-modified messenger ribonucleic acid (mRNA; 2.7 times the amount of nucleoside-modified mRNA in a full human dose of influenza vaccine mRNA) twice prior to mating and twice during gestation. The study revealed no evidence of harm to the fetus due to the vaccine.

Influenza vaccine mRNA is not approved for use in persons younger than 50 years of age. It is not known whether the vaccine is excreted in human milk. No human or animal data are available to assess the effects of influenza vaccine mRNA on the breastfed infant or on milk production/excretion.

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for influenza vaccine mRNA and any potential adverse effects on the breastfed infant from the vaccine or from the underlying maternal condition. For preventive vaccines, the underlying maternal condition is susceptibility to disease prevented by the vaccine.

Of the 20,350 participants 50 years of age and older who received influenza vaccine mRNA in the principal efficacy study in adults 50 through 64 years of age, 9,726 (47.8%) were 65 years of age and older and 2,354 (11.6%) were 75 years of age and older. Of the 1,502 participants 65 years of age and older who received Moderna mRNA quadrivalent influenza vaccine during the 2023-2024 influenza season in a study in adults 65 years of age and older, 326 (21.7%) were 75 years of age and older